Refine by
Metabolic Clinical Articles & Analysis
22 news found
In parallel, the ongoing Phase III clinical development programs (ARANOTE and ARASEC) with darolutamide aim to broaden its use even further by offering treatment options in the metastatic hormone-sensitive setting without concomitant chemotherapies. ...
ByBayer AG
The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular and metabolic disease indications with a clinical-stage pipeline that includes therapeutics for Pompe disease, Parkinson’s disease and congestive heart failure. ...
ByBayer AG
CAMP is the largest clinical study of the metabolism of children with ASD conducted to date by more than 500 patients. ...
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). As ...
Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. ...
ByxCures
“Shirly’s leadership and vision over the last five years have played a vital role building a highly efficient drug discovery organization that today has multiple programs in the clinic,” said Jay Galeota, president and CEO, Kallyope. “As a result, we are entering a new phase of expansion that calls for key new hires. Jiajun and Mike strengthen our ...
” Based on these supportive preclinical results, along with encouraging Phase 1 results, Inversago is looking forward to launching Phase 2 clinical development for INV-202. About INV-202 INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic ...
On the basis of clinical success and acknowledged leadership in the field of celiac disease, the organizers of the International Celiac Disease Symposium (ICDS) have invited Jack Syage PhD, CEO of ImmunogenX, to deliver a panel talk and join the Conference Faculty. ...
He serves as a reviewer for many journals including Diabetes, Pediatric Diabetes, and the Journal of Clinical Endocrinology and Metabolism. “My laboratory is very excited to collaborate with Dr. ...
The talk will be delivered in the session “Separating the Wheat from the Chaff: Top Clinical Abstracts in Celiac Disease,” on May 24, 2022 from 2:00 pm to 3:30 pm PDT. ...
The data revealed a significant normalization of the serum levels of several key metabolites in addition to a significant improvement of patients’ clinical conditions for the duration of the ILB® treatment period. ...
The Mayo and ImmunogenX team creatively persevered despite these challenging conditions to bring this trial to a successful conclusion.” Mayo Clinic Principal Investigator, Joseph A. Murray, MD, states “Latiglutenase is proving to be a leading therapeutic candidate for celiac disease patients as an adjunct to a gluten-free diet. ...
The company was also awarded a Tibbetts for its very successful application of three National Institutes of Health (NIH) grants, each funding Phase 2 clinical trials for the company’s therapeutic candidate latiglutenase for the treatment of celiac disease (CD). ...
(Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced the publication of clinical results from the investigator-initiated INSPIRE clinical trial conducted in collaboration with Fractyl. ...
ImmunogenX is pleased to announce a publication from its team that applies a new algorithm to recent clinical data to further elucidate on this relationship [J.A. Syage and P.T. ...
Principal Investigator, Joseph A. Murray MD of the Mayo Clinic, comments “The investigative team is happy to get the go ahead from the DSMB whose analysis of data thus far has found that the study merits ...
Because of liver enzyme elevations identified during clinical studies, further development was halted. Evaluation of antiprogestin pharmacology and pharmacokinetic data suggested that liver enzyme elevations might be related to off-target or metabolic effects associated with clinical drug exposure. ...
There is increasing evidence for the role of the gut in metabolic diseases, and data from earlier clinical studies of Revita DMR is encouraging. ...
ImmunogenX is pleased to announce that patient enrollment has begun for a Phase 2b clinical trial (NCT04243551, named “Solutions for Celiac”™). ...
Continued analysis of samples from the Children’s Autism Metabolome Project (CAMP), the most comprehensive clinical study of metabolism in children who have autism spectrum disorder (ASD) conducted to date, has identified three new areas of metabolism that affect the biology of children with ASD. ...